ストックスクリーナーアプリを入手
65.89
0.64%
0.42
プレマーケット:
66.37
0.48
+0.73%
Bristol Myers Squibb Co (BMY) 最新ニュース
New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs - Benzinga
Legal intelligence start-up Theo Ai appoints former Bristol Myers Squibb GC to board of directors - The Global Legal Post
Bristol-Myers Squibb stock rating held at Market Perform by Raymond James - Investing.com
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings? - TradingView
Theo Ai Appoints Ex-Bristol Myers Squibb GC To Board - Law360
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board - citybiz
Bristol-Myers Squibb stock hits 52-week high at 62.89 USD - Investing.com
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge - Investing.com
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com - Investing.com India
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board of Directors - citybiz
Bristol Myers Squibb stock holds gains as Takeda partnership and Revlimid erosion shape outlook - Ad-hoc-news.de
Theo Ai Bolsters Leadership, Appoints Sandra Leung, Former Bristol Myers Squibb General Counsel, to Board of Directors - PR Newswire
BMS launches dual immunotherapy for metastatic melanoma - The Hindu
Bristol Myers Squibb stock reacts to latest Opdivo data and solid 2024 outlook - Ad-hoc-news.de
BMY|Bristol-Myers Squibb Co|Price:62.090|Chg%:+0.580 - TradingKey
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo anchor earnings and guidance - Ad-hoc-news.de
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol Myers Squibb stock reacts as cancer and cardiovascular pipeline updates follow recent earnin - Ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Income Statement - TradingKey
Bristol-Myers Squibb Co (BMY) Cash Flow - TradingKey
Bristol-Myers Squibb’s High Dividend Temporarily Backed by Financial Support, but Patent Cliff Poses Future Concerns - NAI500
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Bristol-Myers Squibb Co (BMY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol-Myers Squibb Co (BMY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bristol-Myers Squibb Company (BRM.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BMY|Bristol-Myers Squibb Co|Price:62.560|Chg%:+0.470 - TradingKey
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis underpin revenue and margins - Ad-hoc-news.de
Bristol Myers Squibb stock steadies as investors weigh Karuna buyout and latest oncology data - AD HOC NEWS
Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Public Employees Retirement System of Ohio Has $51.79 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co. - MarketBeat
Why Is Bristol Myers Squibb (NYSE:BMY) On S&P 500 Radar? - Kalkine Media
Compound Planning Inc. Has $4.94 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Arrowstreet Capital Limited Partnership Has $538.13 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb stock trades steady as cardiovascular and oncology pipeline shapes outlook - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DOL Brief Sides With Bristol-Myers in PRT Appeal - planadviser
Bristol Myers Squibb stock steadies as investors weigh Revlimid erosion against new product launches - AD HOC NEWS
DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal - plansponsor
DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
Bristol Myers Squibb stock stabilizes as Eliquis and Opdivo help offset Revlimid erosion - AD HOC NEWS
Donald TrumpBRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
Bristol Myers Squibb stock steadies as Eliquis and Opdivo shape earnings outlook - AD HOC NEWS
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued? - simplywall.st
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub - Yahoo Finance Singapore
Bristol Myers Squibb stock edges higher as recent results and oncology portfolio shape investor view - AD HOC NEWS
Bristol Myers Squibb Partners With NVIDIA to Build Pharma's Largest Supercomputer - Mjengo Hub
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Sahm
Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery - Yahoo Finance UK
Bristol Myers Squibb stock trades steadily as oncology and immunology portfolio supports earnings tr - AD HOC NEWS
Bristol Myers Squibb stock trades steadily as oncology pipeline and recent earnings shape sentiment - AD HOC NEWS
Bristol Myers Squibb stock trades steadily as oncology pipeline and Revlimid erosion shape outlook - AD HOC NEWS
BMS: Boosting AI Drug Discovery Capacity with NVIDIA Tech - Healthcare Digital
Bristol Myers Squibb Expands AI Infrastructure With NVIDIA to Build AI Factory for Drug Discovery - Digital Health News
Bristol Myers Squibb buys Nvidia AI system for drug discovery - AI News
Bristol Myers Squibb stock trades steady as oncology pipeline and recent results frame investor focu - AD HOC NEWS
Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's. - drugdiscoverytrends.com
Bristol Myers Squibb (BMY) Enhances AI Capabilities with New NVI - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
BMS Expands AI Partnership with NVIDIA to Speed Drug Discovery - New Jersey Business & Industry Association
Bristol Myers Squibb stock steadies as investors weigh Opdivo growth and pending Karuna Therapeutics - Ad-hoc-news.de
BMS expands NVIDIA tie-up with Vera Rubin AI factory - The Pharma Letter
Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec - Pharmaceutical Executive
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA - BioSpace
Bristol Myers Squibb stock holds steady as Eliquis and Opdivo underpin earnings outlook - Ad-hoc-news.de
1.52%
5.97%
大文字化:
|
ボリューム (24 時間):